On July 9, Akeso rose 3.32% in regular trading, trading at 99.05 HKD/share, with turnover of HK$219 million. The stock gained momentum from continued policy catalysts in the innovative drug payment reform space, coupled with broader biotech sector strength.

On the news front, the National Healthcare Security Administration previously released preliminary review results for the medical insurance catalog, with 557 drugs passing the initial review and 54 drugs passing the commercial insurance innovative drug catalog review. This marks the substantive advancement of the dual medical insurance plus commercial insurance catalog negotiation framework. Simultaneously, new mechanisms including a pre-declaration system and 8-year price protection have been implemented, providing stable policy expectations for innovative drug commercialization.

At the company level, all indications of Akeso's five self-developed new drugs have been included in the national medical insurance catalog. Its new drug Qiyoukang has completed its first nationwide batch delivery, which is expected to accelerate market penetration. Multiple brokerages maintain Buy ratings on the company, citing its globally leading bispecific antibody technology platform and robust pipeline covering major indications in oncology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)